Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMOS2 for recurrent IDH-mutant lower-grade glioma
ACTRN12623000096651Phase 2Recruiting
- Sponsor
- The University of Sydney
- Start
- Sep 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of paxalisib, cadonilimab, selinexor and niraparib in glioma (4 arms), sponsored by The University of Sydney. Primary endpoint: Progression-free survival at 6 months. Started Sep 2023; status: recruiting.
02
Drugs
paxalisibcadonilimabselinexorniraparib
03
Conditions
glioma
Beyond the preview
Go deeper on ACTRN12623000096651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000096651.